Can lattice radiation boost immunotherapy to shrink lung tumors before surgery?

This phase II trial is testing whether a novel radiation technique called spatially fractionated radiotherapy (SFRT), which delivers alternating high and low doses inside the tumor, can work together with the immunotherapy drug tislelizumab and standard chemotherapy to shrink large stage III non-small cell lung cancers before surgery. The goal is to see if this combination can reduce the tumor enough that very few cancer cells remain at the time of surgery, potentially improving long-term outcomes. The study enrolls adults with potentially resectable bulky tumors (larger than 5 cm) who have not had prior treatment, and will monitor for side effects and how well the cancer responds.